Novo Nordisk VP-biopharmaceuticals
Executive Summary
Novo Nordisk appoints Edward Williams to replace Michael Shalmi as VP-biopharmaceuticals effective April 24. His position will include overseeing the company's hemostasis and growth hormone therapy treatments, and the identification of new project opportunities. Williams was formerly VP-sales for Novartis' respiratory and dermatology business units...